149 related articles for article (PubMed ID: 11914641)
21. Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
ten Tije AJ; Synold TW; Spicer D; Verweij J; Doroshow JH; Sparreboom A
Invest New Drugs; 2003 Aug; 21(3):291-8. PubMed ID: 14578679
[TBL] [Abstract][Full Text] [Related]
22. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
24. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
25. Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol.
Chen Y; Huang W; Chen F; Hu G; Li F; Li J; Xuan A
Cancer Med; 2016 Dec; 5(12):3564-3571. PubMed ID: 27878971
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types.
Reinecke P; Schmitz M; Schneider EM; Gabbert HE; Gerharz CD
Cancer Invest; 2000; 18(7):614-25. PubMed ID: 11036469
[TBL] [Abstract][Full Text] [Related]
27. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
28. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
[TBL] [Abstract][Full Text] [Related]
29. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles.
Hemauer SJ; Patrikeeva SL; Nanovskaya TN; Hankins GD; Ahmed MS
Biochem Pharmacol; 2009 Nov; 78(9):1272-8. PubMed ID: 19591810
[TBL] [Abstract][Full Text] [Related]
30. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Gao J; Murase O; Schowen RL; Aubé J; Borchardt RT
Pharm Res; 2001 Feb; 18(2):171-6. PubMed ID: 11405287
[TBL] [Abstract][Full Text] [Related]
31. A unique interaction between polyamine and multidrug resistance (P-glycoprotein) transporters in cultured Chinese hamster ovary cells transfected with mouse mdr-1 gene.
Aziz SM; Worthen DR; Yatin M; Ain KB; Crooks PA
Biochem Pharmacol; 1998 Jul; 56(2):181-7. PubMed ID: 9698071
[TBL] [Abstract][Full Text] [Related]
32. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
33. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
34. Effects of cysteine on the pharmacokinetics of paclitaxel in rats.
Lee YK; Han SY; Chin YW; Choi YH
Arch Pharm Res; 2012 Mar; 35(3):509-16. PubMed ID: 22477198
[TBL] [Abstract][Full Text] [Related]
35. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
36. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS).
Dintaman JM; Silverman JA
Pharm Res; 1999 Oct; 16(10):1550-6. PubMed ID: 10554096
[TBL] [Abstract][Full Text] [Related]
38. 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo.
Chow EC; Durk MR; Cummins CL; Pang KS
J Pharmacol Exp Ther; 2011 Jun; 337(3):846-59. PubMed ID: 21421739
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
40. Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells.
Ding Q; Niu P; Zhu Y; Chen H; Shi D
J Nat Med; 2022 Jan; 76(1):220-233. PubMed ID: 34751899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
